A beginners guide to chemokines

Future Medicinal Chemistry

Volumn 4, Issue 7, 2012, Pages 845-852

  Vinader, Victoria ^a   Afarinkia, Kamyar ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; GLYCOSAMINOGLYCAN;

HUMAN; INFECTION; INFLAMMATION; NEOPLASM; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; COMMUNICABLE DISEASE; IMMUNOLOGY; PROTEIN CONFORMATION;

ANIMALS; CHEMOKINES; COMMUNICABLE DISEASES; HUMANS; INFLAMMATION; MODELS, MOLECULAR; NEOPLASMS; PROTEIN CONFORMATION; RECEPTORS, CHEMOKINE;

EID: 84861082486     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.49     Document Type: Review

References (55)

1. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 12, 121-127 (2000
2. Ulmvar MH, Hub E, Rot A. Atypical chemokine receptors. Exp. Cell Res. 317, 556-568 (2011
3. Lalani AS, McFadden G. Evasion and exploitation of chemokines by viruses. Cytokine Growth Factor Rev. 10, 219-233 (1999
4. Pleskoff O, Tréboute C, Brelot A, Heveker N, Seman M, Alizon M. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 276, 1874-1878 (1997
5. Murphy PM. Pirated genes in Kaposi's sarcoma. Nature 385, 296-299 (1997
6. Kledal TN, Rosenkilde MM, Coulin F et al. A broad-spectrum chemokine antagonist encoded by kaposi's sarcoma-Associated herpes virus. Science 277, 1656-1659 (1997
7. Mantovani A. The chemokine system: Redundancy for robust outputs. Immunol. Today 254-257 (1999
8. Schall TJ, Amanda EI, Proudfoot AEI. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat. Rev. Immunol. 11, 355-363 (2011
9. Blanpain C, Migeotte I, Lee B et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 94, 1899-1905 (1999
10. Koopmann W, Krangel MS. Identification of a glycosaminoglycan-binding site in chemokine macrophage inflammatory protein-1alpha. J. Biol. Chem. 272, 10103-10109 (1997
11. Stringer SE, Forster MJ, Mulloy B et al. Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1a. Blood 100, 1543-1550 (2002
12. Vives RR, Crublet E, Andrieu JP et al. A novel strategy for defining critical amino acid residues involved in protein/glycosaminoglycan interactions. J. Biol. Chem. 279, 54327-54333 (2004
13. Martin L, Blanpain C, Garnier P, Wittamer V, Parmentier M, Vita C. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry 40, 6303-6318 (2001
14. Proudfoot AE, Fritchley S, Borlat F et al. The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity. J. Biol. Chem. 276, 10620-10626 (2001
15. Chakravarty L, Rogers L, Quach T, Breckenridge S, Kolattukudy PE. Lysine 58 and histidine 66 at the C-Terminal a-helix of monocyte chemoattractant protein-1 are essential for glycosaminoglycan binding. J. Biol. Chem. 273, 29641-29647 (1998
16. Lau EK, Paavola CD, Johnson Z et al. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: Implications for structure and function in vivo. J. Biol. Chem. 279, 22294-22305 (2004
17. Sadir R, Baleux F, Grosdidier A, Imberty A, Lortat-Jacob H. Characterization of the stromal cell-derived factor-1a-heparin complex. J. Biol. Chem. 276, 8288-8296 (2001
18. Kuschert GSV, Hoogewerf AJ, Proudfoot AE et al. Identification of a glycosaminoglycan binding surface on human interleukin-8. Biochemistry US 37, 11193-11201 (1998
19. Krieger E, Geretti E, Brandner B, Goger B, Wells TN, Kungl AJ. A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: Support from isothermal fluorescence titrations. Proteins 54, 768-775 (2004
20. Peterson FC, Elgin ES, Nelson TJ et al. Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J. Biol. Chem. 279, 12598-12604 (2004
21. Shaw JP, Johnson Z, Borlat F et al. The x-ray structure of RANTES: Heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure 12, 2081-2093 (2004
22. Laguri C, Arenzana-Seisdedos F, Lortat-Jacob H. Relationships between glycosaminoglycan and receptor binding sites in chemokines-The CXCL12 example. Carbohyd. Res. 343, 2018-2023 (2008
23. Ali S, Robertson H, Wain JH, Isaacs JD, Malik G, Kirby JA. A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. J. Immunol. 175, 1257-1266 (2005
24. Graham GJ, Wilkinson PC, Nibbs RJ et al. Uncoupling of stem cell inhibition from monocyte chemoattraction in MIP-1a by mutagenesis of the proteoglycan binding site. EMBO J. 15, 6506-6515 (1996
25. Kuschert GSV, Coulin F, Power CA et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38, 12959-12968 (1999
26. Pease JE, Wang J, Ponath PD, Murphy PM. The N-Terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation. J. Biol. Chem. 273, 19972-19976 (1998
27. Han KH, Green SR, Tangirala RK, Tanaka S, Quehenberger O. Role of the first extracellular loop in the functional activation of CCR2: The first extracellular loop contains distinct domains necessary for both agonist binding and transmembrane signalling. J. Biol. Chem. 274, 32055-32062 (1999
28. Soriano S F, Serrano A, Hernanz-Falcón P et al. Chemokines integrate JAK/STAT and G-protein pathways during chemotaxis and calcium flux responses. Eur. J. Immunol. 33, 1328-1333 (2003
29. Wu B, Chien EY, Mol CD et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 1066-1071 (2010
30. Scalzo P, de Miranda AS, Guerra Amaral DC, de Carvalho Vilela M, Cardoso F, Teixeira AL. Serum levels of chemokines in Parkinson's disease. Neuroimmunomodulation 18, 240-244 (2011
31. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 98, 1652-1658 (2007
32. Giles R, Loberg RD. Can we target the chemokine network for cancer therapeutics? Curr. Cancer Drug Target. 6, 659-670 (2006
33. Wu XS, Lee VC, Chevalier E, Hwang ST. Chemokine receptors as targets for cancer therapy. Curr. Pharm. Design 15, 742-757 (2009
34. Arya M, Ahmed H, Silhi N, Williamson M, Patel HRH. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumor Biol. 28, 123-131 (2007
35. Liu JQ, Merritt JR. CC chemokine receptor small molecule antagonists in the treatment of rheumatoid arthritis and other diseases: A current view. Curr. Top. Med. Chem. 10, 1250-1267 (2010
36. Koelink PJ, Overbeek SA, Braber S et al. Targeting chemokine receptors in chronic inflammatory diseases: An extensive review. Pharmacol. Ther. 133, 1-18 (2012
37. Kotb M, Calandra T. Cytokines and Chemokines in Infectious Diseases Handbook. Kotb M, Calandra T (Eds). Humana Press, Totowa, NJ, USA (2003
38. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B. CCR5 is characteristic of Th1 lymphocytes. Nature 391, 344-345 (1998
39. Bonecchi R, Bianchi G, Bordignon PP et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187, 129-134 (1998
40. Zingoni A, Soto H, Hedrick JA et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J. Immunol. 161, 547-551 (1998
41. Bachmann MF, Kopf M, Marsland BJ. Chemokines: More than just road signs. Nat. Rev. Immunol. 6, 159-164 (2006
42. Raman D, Sobolik-Delmaire T, Richmond A. Chemokines in health and disease. Exp. Can. Res. 317, 575-589 (2011
43. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2000
44. Wang B, Hendricks DT, Wamunyokoli F, Parker IM. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res. 66, 3071-3077 (2006
45. Huang JT, Yao JL, Zhang L et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am. J. Pathol. 166 1807-1815 (2005
46. Zhu YM, Webster SJ, Flower D, Woll PJ. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br. J. Cancer 91, 1970-1976 (2004
47. Gabellini C, Trisciuoglio D, Desideri M et al. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur. J. Cancer 45, 2618-2627 (2009
48. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur. J. Cancer 42, 768-778 (2006
49. Stewart TJ, Smyth MJ. Chemokine-chemokine receptors in cancer immunotherapy. Immunotherapy 1, 109-127 (2009
50. Richmond A. Chemokine modulation of the tumor microenvironment. Pigment Cell Melanoma Res. 23, 312-313, (2010
51. Krieg C, Boyman O. The role of chemokines in cancer immune surveillance by the adaptive immune system. Semin. Cancer Biol. 19, 76-83 (2009
52. Pivarcsi A, Muller A, Hippe A et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc. Natl Acad. Sci. USA 104, 19055-19060 (2007
53. Wilson CR, Wilson TR, Johnston PG, Longley DB, Waugh DJ. Interleukin-8/CXCR2 signaling plays an important role in conferring resistance of prostate cancer cells to chemotherapy. Mol. Cancer Ther. 6, 3394S-3395S (2007
54. Tetu B, Popa I, Bairati I et al. Immunohistochemical analysis of possible chemoresistance markers identified by micro-Arrays on serous ovarian carcinomas. Modern Pathol. 21, 1002-1010 (2008
55. Waugh DJ, Wilson C. The interleukin-8 Pathway in Cancer. Clin. Cancer Res. 14, 6735-6741 (2008).